Abnova — Interim / Quarterly Report 2016

Aug 31, 2016

==> picture [794 x 119] intentionally omitted <==

==> picture [794 x 359] intentionally omitted <==

1

Safe Harbor Notice

The following pages contain projections & estimates of financial information as well as market and product developments for future periods. These projections & estimates are based on information currently available which we believe to be reliable, but they involve risks & uncertainties. Our actual results of operations & financial condition may differ significantly from those contained in the projections & estimates. The projections & estimates should not be interpreted as legally binding commitments, but rather as flexible information subject to change occasionally.

2

Agenda

✓ Company Overview

✓ Q2&H1-2016 Financial Results

✓ Abnova’s Opportunities in Precision Medicine

✓ Q&A

3

Abnova Company Profile

==> picture [462 x 460] intentionally omitted <==

==> picture [273 x 364] intentionally omitted <==

4

Consolidated Income Statement Q2&H1-2016

									In NT$K
	Q2‘16	%	Q2’15	%	H1‘16	%	H1’15	%	H1 YOY
Net Sales	111,519	100.0%	123,189	100.0%	229,327	100.0%	234,425	100.0%	(2.2%)
Cost of Goods Sold	(60,178)	(54.0%)	(51,297)	(41.6%)	(121,763)	(53.1%)	(118,343)	(50.5%)	2.9%
Gross Profit	51,341	46.0%	71,892	58.4%	107,564	46.9%	116,082	49.5%	(7.3%)
Operating Expense	(42,399)	(38.0%)	(40,079)	(32.5%)	(80,606)	(35.1%)	(79,450)	(33.9%)	1.5%
Operating Income	8,942	8.0%	31,813	25.8%	26,958	11.8%	36,632	15.6%	(26.4%)
Non Operating Income	383	0.3%	(474)	(0.4%)	(407)	(0.2%)	(4,565)	(1.9%)	(91.1%)
Income before Tax	9,325	8.4%	31,339	25.4%	26,551	11.6%	32,067	13.7%	(17.2%)
Income after Tax	13,216	11.9%	25,406	20.6%	27,876	12.2%	25,997	11.1%	7.2%
Basic EPS after Tax	0.23		0.43		0.48		0.44

5

Revenue Breakdown by Product

==> picture [794 x 404] intentionally omitted <==

----- Start of picture text -----

In NT$K 2016H1
500000
3,362 15,166 4.5%
400000 69,294 69,539
3.6%
15.4%
300000
8,262
200000
35,269
76.5%
100000
364,038 365,017 175,502
0
2014 2015 2016H1
Antibody&Reagent Protein Antibody&Reagent Protein
CTC instrument Others CTC instrument Others
----- End of picture text -----

6

Precision Medicine

What is Precision Medicine?

• Until now, most medical treatments have been designed for the “average patient.” As a result of this “one-size-fits-all” approach, treatments can be very successful for some patients but not for others.

• Precision Medicine , on the other hand, is an innovative approach that takes into account individual differences in people’s genes, environments, and lifestyles.

Why Precision Medicine?

• Precision medicine gives clinicians tools to better understand the complex mechanisms underlying a patient’s health, disease, or condition, and to better predict which treatments will be most effective.

• President of United State of America, Barack Obama, 2015

7

US Precision Medicine Initiative

2011– America Medical Association announced the concept of precision medicine for the first time.

2014– National Cancer Institute has launched a series of precision medicine clinical trial.

Jan. 2015– President Obama announced the launching of the “Precision Medicine Initiative” (PMI) at State of the Union address. 2016 United States federal budget plan includes the allocation of $215 million funding to support the development of precision medicine related research.

Mar. 2015– Establishing PMI Working Group of the Advisory Committee to the Director (ACD) to develop a framework for creating and managing a large research cohort to understand the variables that contribute to health and disease.

Feb. 2016- The White House hosts a Precision Medicine Initiative Summit on one year anniversary of the launch of PMI.

Mission Statement

“To enable a new era of medicine through research, technology, and policies that empower patients, researchers, and providers to work together toward development of individualized care.”

8

China Foresees the Market of Precision Medicine

2006– China has advocated the concept of precision surgery, having it recognized by domestic and international medical professionals, precision surgery has been widely applied in radiotherapy, gynecology, etc.

– Feb. 2015 Xi Jinping, the General Secretary of the Communist Party of China, instructed the Ministry of Science and Technology of the People’s Republic of China and the National Health and Family Planning Commission of the People’s Republic of China to establish a 19 member National Precision Medical Committee.

Mar. 2015– The Ministry of Science and Technology of the People’s Republic of China held the first National Precision Medical Committee Meeting and decided the allocation of 600 million RMB into the field of precision medicine.

– Dec. 2015 Officially Establish the “Chinese Personalized TreatmentPrecision Medicine Biotech Industry Alliance“ in Shanghai.

It is a beginning of a new era of “Precision Medicine”, the State Council of the People’s Republic of China will allocate 600 million RMB by the year of 2030.

9

Abnova’s Stance in Precision Medicine

==> picture [794 x 121] intentionally omitted <==

----- Start of picture text -----

Precision Medicine
----- End of picture text -----

Abnova Mission Statement

Leverage diagnostic testing to diagnose and predict individuals’ susceptibility to a particular disease and select optimal therapies based on the context of their genetic content, thereby maximizing treatment response while minimizing side effect and resistance.

10

China Prenatal & Cancer Precision Medicine Markets

Prenatal Genetic Testing

• According to National Bureau of Statistics of the People’s Republic of China, the number of newborns nationwide is 16.87 million in 2014. After ending its one-child policy, It’s been predicted the number of newborns will grow significantly.

• Subject to government approval, prenatal genetic testing has become more common in China.

Cancer Detection

• According to the International Agency for Research on Cancer, an estimated 2.2 million deaths each year in China are attributed to cancer. By the year of 2030, there will be a 5 million cancer patients each year and the number of deaths is approximately 3.5 million people.

• “The growth of cancer in China is ferocious”, said Dr. Bernhard Schwartlande, WHO representative in China.

11

Applications of Prenatal & Cancer Precision Medicine

Precision Medicine

Prenatal

Prevention and Detection

Cancer Prevention and Detection

1. Amniocentesis (Invasive Prenatal Testing)

2. NIPT (Non-Invasive Prenatal Testing)

3. NIPD (Non invasive prenatal diagnosis)

4. Early Cancer

5. Cancer Metastasis

6. Treatment Guidance

7. Treatment Response

8. Drug Resistance

9. Cancer Relapse

12

Comparison of Prenatal Genetic Testings

Prenatal Genetic Testing

NIPT NIPD Amniocentesis (Non-Invasive (Non invasive Prenatal Testing) prenatal diagnosis) Advantages: Advantages: Advantages: 1. Intact Genetic Structure 1. Non-Invasive 1. Non-Invasive 2. High precision 2. Performed at 10-12 weeks 2. Intact Genetic Structure 3. Performed at 6-12 weeks Disadvantages: Disadvantages: 4. No risk to Pregnancy 1. Invasive 1. Fragmented Genetic Structure 2. Performed at 16-18 weeks 2. Restricted to chromosomes 13, Disadvantages: 3. High risk to Pregnancy 18, 21, 1. Technical entry barrier 2. Higher Cost

13

Evolution of Tissue to Cell-Based Cancer Testings

Cancer Testing

==> picture [794 x 318] intentionally omitted <==

----- Start of picture text -----

Tissue-Based Cell-Based
Companion Diagnostics Companion Diagnostics
Advantages:
Advantages:
1. Non-invasive
1. High precision
2. Real-time
3. DNA source known
Disadvantages:
1. Invasive 4. High precision
2. One moment in time 5. High specificity
Disadvantages:
1. Technical entry barrier
2. Require cell isolation
----- End of picture text -----

14

Current Companion Tissue Biomarkers & Personalized Therapies

	Genetic Biomarker Required Companion Diagnostic Drug Drug Manufacturer
	t(15;17) chromosome translocation or PML/RARα gene expression in acute promyelocytic leukemiaPML/RARα Vesanoid® (tretinoin), Trisenox® (arsenic trioxide) Roche, Cell Therapeutics, Inc Overexpression of HER-2 in metastatic breast cancer tumor cells HercepTest™ Herceptin (trastuzumab), Tykerb (lapatinib) Genentech, GlaxoSmithKline Philadelphia chromosome positive [BCR-ABL+] chronic myeloid leukemia in chronic phase BCR-ABL Gleevec® (imatinib) Novartis
	Platelet-derived growth factor receptor (PDGFR) gene rearrangements in myelodysplastic/myeloproliferative diseases PDGFR Gleevec® (imatinib) Novartis Hodgkin’s lymphoma cells expressing CD20 antigen CD20 Bexxar® (tositumomab) Corixa High expression of EGFR (more likely to respond)DakoCytomation EGFR pharmDx™ test kit Erbitux® (cetuximab), Vectibix® (panitumumab) Eli Lilly, Amgen Chromosome 5q deletion associated with transfusion-dependent anemia due to low- or
	intermediate-1-risk MDS, with/without additional cytogenetic abnormalities 5q deletion Revlimid® (lenalidomide) Celgene Corporation Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy BCR-ABL Sprycel® (dasatinib) Bristol-Myers Squibb Expression of CD25 component of IL-2 receptor in persistent or recurrent cutaneous T-cell lymphoma CD25 Ontak® (denileukin diftitox) Eisai Medical Research
	ELM4-ALK translocation-positive advanced or metastatic non-small cell lung cancer ELM4-ALK translocation Xalkori® (crizotinib) Pfizer BRAF V600E mutation in unresectable or metastatic melanoma BRAF V600E mutation Zelboraf™ (vemurafenib) Genentech (Roche)

Curr Top Genet. (2012) 5: 23

15

Abnova Market Strategy in Precision Medicine

Territory

• China: East China (Jiangsu, Zhejiang), North China (Hebei, Shanxi), Northwest China (Shanxi), Southwest China (Sichuan, Yunnan), Northeast China (Heilongjiang)

• • Japan: Kanto (Tokyo), Kansai (Osaka)

Alliance

• Localization Alliance & Join Venture

• Channel (Agent、Distributor), Project Development

• Establishment of Third Party Precision Medicine Join Laboratory

• Revenue Contribution

• Clinical Research (Short-Term)

• In Vitro Diagnostics (Mid-Term)

• Drugs (Long-Term)

16

==> picture [794 x 119] intentionally omitted <==

==> picture [794 x 359] intentionally omitted <==

17

Abnova Core Competence in Precision Medicine A Vertically Integrated In Vitro Diagnostic Company

==> picture [794 x 121] intentionally omitted <==

In Vitro Diagnostics ACTN4 Tissue Biomarker System Integration TGFB1 Tissue Biomarker GMP Bioreagents CSV TTF1 T790M CTC Biomarker Instrumentations CSV CD133 CTC Biomarker Softwares fNRBC CFC Biomarker

Antibody Bank One Gene One Antibody Resource & Support

18

Abnova Actinin-4 (ACTN4) Tissue Biomarker

• Actin-binding protein associated with enhanced cell motility.

• Overexpression closely associated with a poor outcome in patients with lung adenocarcinoma.

• World’s first tissue predictive biomarker for adjuvant chemotherapy

==> picture [307 x 323] intentionally omitted <==

==> picture [205 x 166] intentionally omitted <==

==> picture [205 x 171] intentionally omitted <==

ACTN4 DNA (Target for FISH) ACTN4 Protein (Target for IHC)

Cell Biosci. (2015) 5: 41

19

Poor 5 Year Survival Rate in 6644 Resected NSCLC: A Japanese Lung Cancer Registry Study

==> picture [794 x 121] intentionally omitted <==

==> picture [393 x 148] intentionally omitted <==

IA 79.5% (n = 2009) IB 60.1% (n = 1418) IIA 59.9% (n = 232) IIB 42.2% (n = 757) IIIA 29.8% (n = 1250) IIIB 19.3% (n = 719) IV 20.0% (n = 259).

==> picture [393 x 148] intentionally omitted <==

Lung Cancer (2005) 50: 227

20

ACTN4 as Predictive Tissue Biomarker for Stage I Lung Adenocarcinoma Adjuvant Chemotherapy Retrospective Preclinical Trial: ACTN4 Expression & Cisplatin Doublet

==> picture [454 x 13] intentionally omitted <==

----- Start of picture text -----

A B C
----- End of picture text -----

==> picture [689 x 257] intentionally omitted <==

Oncotarget. (2016) Epub ahead of print

21

ACTN4 as Predictive Tissue Biomarker for Stage II & IIIA Lung Adenocarcinoma Adjuvant Chemotherapy

Retrospective Preclinical Trial: ACTN4 Expression & Cisplatin Doublet

==> picture [628 x 348] intentionally omitted <==

J Clin Oncol (2016) Meeting Abstract May 2016 vol. 34 no. 15_suppl e20003

22

Abnova TGFB1 Tissue Biomarker

• Secreted protein associated with cellular functions, including cell growth, cell proliferation, cell differentiation and apoptosis.

• TGFβ signaling inhibition is an emerging strategy for cancer immunotherapy.

• World’s first TGFB1 specific monoclonal antibody for immunohistochemistry.

==> picture [794 x 358] intentionally omitted <==

----- Start of picture text -----

Latent TGFB1
(LAP1)
(Target for IHC)
Pan-TGFB
(Target for IHC)
23
----- End of picture text -----

Idiopathic Pulmonary Fibrosis (IPF)

• BNC-1021 is a revolutionary inhalant RNAi therapy for IPF

• BNC-1021 specifically targets TGFB1 mRNA without interferon response

• BNC-1021 has less immunological response than common siRNA

==> picture [794 x 239] intentionally omitted <==

*BNC-1021 Proprietary RNAi (Bonac, Japan)

24

TGF-1 as Predictive Tissue Biomarker for Idiopathic Pulmonary Fibrosis (IPF)

TGF-1 Overexpression

==> picture [185 x 160] intentionally omitted <==

----- Start of picture text -----

TGF-  TGF- 
TGF-  TGF- 
TGF-  TGF- 
TGF-  TGF- 
TGF-  TGF- 
----- End of picture text -----

==> picture [184 x 199] intentionally omitted <==

----- Start of picture text -----

TGF-1 Normalized
TGF-  TGF- 
TGF-  TGF- 
TGF-  TGF- 
TGF-  TGF- 
TGF-  TGF- 
----- End of picture text -----

==> picture [794 x 120] intentionally omitted <==

*BNC-1021 Proprietary RNAi (Bonac, Japan)

*Representative IHC images of fibrotic conditions corresponding to TBF-1 expression level. Images adapted from: Lee, C.G. et al. J. Exp. Med., (2001)

25

Tissue vs. Liquid Biopsy in Precision Medicine

Tissue Biopsy

Liquid Biopsy

• Invasive  Non-invasive cannot always be

• Painful performed  Time saving  Costly  Real-time monitoring  Takes time  Regular monitoring  Risky

==> picture [766 x 113] intentionally omitted <==

• Not enough tissue sample available

• Liquid Biopsy is  Not enough tumor tissue in the sample useful when there is:  A hard-to-reach tumor  Need for regular monitoring

26

Comparison of Liquid Biopsies

==> picture [794 x 466] intentionally omitted <==

----- Start of picture text -----

Next Generation
Diagnostics
Circulating Cell- Circulating Tumor Circulating
Free DNA, cfDNA Cell, CTC Exosome
Advantages: Advantages: Advantages:
1. Non-invasive 1. Non-invasive 1. Non-invasive
2. Cells not required 2. Real-time 2. Cells not required
3. DNA source known
Disadvantages: 4. High precision Disadvantages:
1. DNA source not known 5. High specificity 1. New technology
2. Require known mutations 2. Isolation cumbersome
2. Lower sensitivity Disadvantages: 3. Biomarkers unknown
3. False positive findings 1. Technical entry barrier
(benign diseases) 2. Require cell isolation
----- End of picture text -----

Sci Transl Med. (2014) 6: 224ra24

27

Liquid Biopsy Applications in Precision Medicine

CTC cfDNA Samples: 1. Blood 2. Urine 3. Other body fluid Exosome Detection Monitoring Early stage detection Treatment response Cancer metastasis Drug resistance Treatment uidance Cancer recurrence g

28

Circulating Tumor Cells (CTC ）

Circulating Tumor Cells (CTCs), originated from primary tumors or metastatic tumors, acquire the ability to shed from basal lamina into vascular or lymphatics.

Previous cancer researches have demonstrated CTCs plays a critical role in metastatic spread of carcinoma. CTCs detection benefits the studies on the mechanism of tumor metastasis, early cancer detection and monitoring, drug selection and monitoring (companion diagnostics) and prognosis. However, the concentration of CTCs in blood is low, in which they are found in frequencies on the order of 1-10 CTC per mL of whole blood in patients with metastatic disease. Therefore, CTC detection greatly depends upon whether enrichment of CTCs can be done with high efficiency and sensitivity.

==> picture [395 x 299] intentionally omitted <==

29

Current CTC Isolation Technologies

Density Gradient

 High Density Liquid

Enrichment

Recovery Layer

==> picture [39 x 124] intentionally omitted <==

Plasma WBC High Density Liquid RBC

• Size-Based Filtration

• Negative Enrichment (Antibody Removal) – Abnova CytoBot™

• Positive Enrichment (Antibody Capture) – Abnova CytoQuest™ CR & Dx

WBC CTC

==> picture [33 x 26] intentionally omitted <==

==> picture [155 x 76] intentionally omitted <==

==> picture [123 x 132] intentionally omitted <==

==> picture [120 x 79] intentionally omitted <==

==> picture [44 x 35] intentionally omitted <==

30

Current CTC Isolation Systems

Oncoquick

ISET

==> picture [794 x 467] intentionally omitted <==

----- Start of picture text -----

Incubate
10 spots = 1 ml blood filtered per spot
10 min
Low density cells,
blood spin Including epithelia
cells, tumor cells, Epithelial cell, tumor cells,
leukocytes, tumor microemboli
platelets Collected for Cytopathological analysis Dilute Filtration with ISET device 3 and “rare” cells
Porous Immunolabelling with buffer min enriched on the filter
Molecular analysis
membrane On the filter:
Cytopathological analysis
Separation
CTC/CTM counting per ml
medium Erythrocytes
Immunolabelling
FISH Mount filter on
TUNEL slide
CellSearch Molecular analysis Cytopathological analysis
Molecular analysis on targeted to tumor cells after laser
Plasma Aspirate after enriched cells from the microdissection
replaced by magnetic Add spots (CGH, DNA mutation, RT‐PCR)
buffer incubation Anti‐CD45‐APC
Anti‐CK‐PE
Add EpCAM DAPI
Ferro‐Fluid
Transfer to
‐Positive selection MagNest
for epithelia cells chamber
‐Negative
selection for
leukocytes
blood
Recovery Magnetic Aspirate enriched Review with
EpCAM+ cells for Wash epithelial cells CellSpotter
molecular analysis to count
epithelial cells
----- End of picture text -----

Cancer Letters (2007) 253: 180

31

CellSearch® CTC Clinical Applications Disease Pro nosis via Cell Enumeration Onl g y

CellSearch® Proprietary Cancers CTC Clinical Applications Capture & Detection Antibodies Capture: EpCAM Prostate Cancer Metastasis - prognosis Detection: Cytokeratin+, CD45-, DAPI+ Capture: EpCAM Breast Cancer Metastasis - prognosis Detection: Cytokeratin+, CD45-, DAPI+ Capture: EpCAM Metastasis – prognosis Colorectal Cancer Detection: Cytokeratin+, CD45-, DAPI+ (poor capture efficiency)

==> picture [794 x 120] intentionally omitted <==

Journal of Oncology (2010) 2010: 617421

32

CTC Needs Bioreagents & Biomarkers to Expand Clinical Applications

==> picture [794 x 359] intentionally omitted <==

J Cell Biol (2011) 192: 373-82.

33

Abnova CytoQuest™ CR Circulating Rare Cells Positive Enrichment & Retrieval System

Integrated System

• Buffer reservoir

• Fluidic pump

• SCx™spiral chamber

• Coupler

• HBx™micromixer

• Chip receptor

• TCx™thermal chuck

• Touch user interface

Antibody-based, cell capture

• Cell enumeration (CytoChipNano)

• Single cell isolation (CytoChipNano)

• Thermal cell release (CytoChipNano CR)

==> picture [794 x 120] intentionally omitted <==

34

Abnova CytoQuest™Dx Circulating Tumor Cell Positive Enrichment & Retrieval Automation

CytoQuest™ Dx Integration

• Total Solution Workstation

• XYZ Axis and 6 Axial Robotic Arm

• In-Process Controls & Sensors

• Intelligent Software Algorithm

• Self-Contained Modules

• RFID Consumable Tracking

• Clean Environment & HEPA Filter

CytoQuest™ Dx Advantages

• Precision, Accuracy, & Reproducibility

• High Throughput & Multi-Tasking

• Minimize Cross Contaminations

• Positive Selection Cell Isolation

==> picture [375 x 211] intentionally omitted <==

35

Abnova’s Bioreagents & Biomarkers Drive Clinical Applications

==> picture [85 x 195] intentionally omitted <==

==> picture [85 x 186] intentionally omitted <==

==> picture [85 x 71] intentionally omitted <==

Circulating Epithelial Cells

CytoQuest™ Epithelial Cell Kit CytoQuest™ Epithelial Cell Kit for Mouse Model

CytoQuest™ Epithelial Cell Solution CytoQuest™ Epithelial Cell Release Kit

CytoQuest™ Plastin-3 EMT Transformed Circulating Epithelial Cell Kit

CytoQuest™ CSV EMT Transformed Circulating Epithelial Cell Kit Circulating Tumor Cells

CytoQuest™ Choriocarcinoma Cell Kit CytoQuest™ Colorectal Cancer Cell Kit CytoQuest™ Hepatocellular Carcinoma Cell Kit CytoQuest™ Pancreatic Cancer Cell Kit CytoQuest™ Prostate Cancer Cell Kit CytoQuest™ Sarcoma Cell Kit

CytoQuest™ Universal Circulating Tumor Cell Kit

Circulating Cancer Stem Cells

CytoQuest™ Clear Cell Renal Cancer Stem Cell Kit CytoQuest™ Universal Cancer Stem Cell Kit

Circulating Trophoblasts

CytoQuest™ Trophoblast Kit

==> picture [85 x 119] intentionally omitted <==

==> picture [85 x 287] intentionally omitted <==

Cell Blockers & Single Cell Picker

CytoQuest™ FcR Blocking Reagent CytoQuest™ Staining Blocker CytoQuest™ SuperBlocker CytoQuest™ Single Cell Picking Kit

FISH Probes

ACTN4 DNA Probe AR/CENXp FISH Probe BRCA1/CEN17q FISH Probe CD274/CEN9q FISH Probe EGFR/CEN7p FISH Probe EML4/ALK Translocation FISH Probe ERG Split FISH Probe HER2/CEN17q FISH Probe MYC/CEN8q FISH Probe p53/CEN17q FISH Probe PTEN/CEN10p FISH Probe TOP2A/CEN17q FISH Probe

Cell Staining Dyes Calcein AM DAPI Hoechst 33342 Propidium Iodide

Abnova Universal CTC, EMT, and CSC Antibody Cell-Surface Vimentin (CSV)

Table 1. Cell-surface vimentin expression analysis in different cancer cell lines[1]

	Cell line CSV	Cell line CSV	Cell line CSV
	Breast	Colon	Brain
	MCF‐7 (H) SKBR3 (H) MDA‐MB‐231 (H) MDA‐MB‐453 (H) MDA‐MB‐458 (H) 4T1 (M) + + + + ++ +	DLD‐1 (H) GEO (H) OS‐187 (H) SW620 (H) SW480 (H) HCT‐116 (H) HT‐29 (H) Caco‐2 (H) CT26 M ++ ++ ++ + + + ++ + +	SKNAS (H) SKNBE2 (H) NGP (H) SH‐SY5Y (H) LAN5 (H) KCN (H) DBT (M) U251 (H) ++ +++ + ++ ++ + + +
	Liver
	AMC14 (M) ++	‐ ()		NOTE:CSV was scored using flow cytometric analysis by measuring mean fluorescence intensity of CSV. Abbreviations: H, human; M, mouse. “+, ++, +++": <2-, <4-, >4-fold presence compared with isotype control.
	Bladder	Pancreas
	RT4V6 (H) T24 (H) + ++	PANC‐1 (H) MiaPACA‐2 (H) ++ +

Table 2. Analysis of sensitivity, specificity, positive predictive value, and negative predictive value for different methods[2]

	Method Sensitivity% Specificity % Positive predictive value, % Negative predictive value, % CSV 85 94.45 97.14 73.91 CellSearch 47.50 83.35 86.37 41.67 Average of 2 methods 82.50 94.45 97.06 70.84 Summation of 2 methods Cutoff 5 CTCs/7.5 mL 92.50 61.12 84.09 78.57
	Cutoff 8 CTCs/7.5 mL 92.50 83.33 92.50 83.33 Ratio* 55 72.23 81.49 41.94

*Ratio of CTC counts from CSV and CellSearch methods in terms of epithelial to mesenchymal ratios.

1. Clinical Cancer Research (2015) 21: 899

2. Clinical Chemistry (2015) 61: 259

37

Comparison with CellSearch® & IsoFlux™

		CellSearch®	IsoFlux™	CytoQuest™ CR
	Sample Volume & Vial	7.5ml (CellSave™)	7-10ml (EDTA)	2ml (Heparin)
	Sample Type & Prep	Whole Blood	Whole Blood+RBC Lysis	Whole Blood+RBC Lysis & WBC Depletion
	Cell Capture Method	Antibody Labeled, Ferrofluid Nanoparticles (nm)	Antibody Labeled, Magnetic Core+Polymer Beads (um)	Antibody Labeled, Nano Arrays (nm)
	Cell Fixation before Isolation	Yes	No	No
	Selection	Capture EpCAM +CK, +DAPI, -CD45	Capture EpCAM +CK, +DAPI, -CD45	Capture EpCAM +CK, +DAPI, -CD45
	Recovery Rate	82% (4-12 SK-BR-3 cells	74% (0-300 PC3 cells spiked	90% (PC9 cells in healthy
		spiked in healthy blood)	in healthy blood)	blood)
	Enumeration	Yes	Yes	Yes (CytoChipNano™)
	Single Cell Isolation	No	No	Yes (CytoChipNano™)
	Cell Retrieval	No	Yes	Yes (CytoChipNano™ CR)
	Biomarker Driven Applications	No	No	Yes

38

CytoQuest™ Cancer Diagnostics

Non-Small Cell Lung Cancer CTC and CD133+ CSC

Cytokeratin – FITC CD45 – PE CD133 – Alexa 647 CD133[+ ] CTC WBC

==> picture [98 x 10] intentionally omitted <==

----- Start of picture text -----

Nucleus – DAPI
----- End of picture text -----

Prostate Cancer CTC and AR Gene Amplification

Cytokeratin – FITC CD45 – PE Nucleus – DAPI Dual–color FISH CTC WBC AR / CEN-X

Pancreatic Cancer CTC, CSV+ EMT CTC, and CD133+ CSC

==> picture [757 x 121] intentionally omitted <==

----- Start of picture text -----

Merged CSC CSV CD133 – Alexa 647 CD45 – PE Nucleus – DAPI
----- End of picture text -----

39

CytoQuest™ Cancer Diagnostics

==> picture [759 x 466] intentionally omitted <==

----- Start of picture text -----

Clear Cell Renal Cell Carcinoma CEC and CD105+ CSC
Merged CD105 – FITC CD45 – PE Nucleus – DAPI
CD105 [+ ] CSC
WBC
Hepatocellular Carcinoma ASGPR+ CTC
Merged Cytokeratin – FITC CD45 – PE Nucleus – DAPI
CTC
WBC
Colorectal Adenocarcinoma CDX2+ CTC
Merged Cytokeratin – FITC CD45 – PE CDX2 – Alexa 647 Nucleus – Hoechst
WBC
CTC
----- End of picture text -----

40

Abnova CytoBot™

Circulating Tumor Cell Negative Enrichment & Retrieval Automation

CytoBot™ Integration

• Total Solution Workstation

• Two 6 Axial Robotic Arms

• In Process Controls & Sensors

• Intelligent Software Algorithm

• Self-Contained Instruments

• Clean Environment & HEPA Filter

CytoBot™ Advantages

• Precision, Accuracy, & Reproducibility

• High Throughput & Multi-Tasking

• Minimize Cross Contaminations

• Negative Selection Cell Isolation

==> picture [306 x 348] intentionally omitted <==

41

CytoBot™Bio-Robotic Workflow

==> picture [794 x 466] intentionally omitted <==

----- Start of picture text -----

Blood Draw
Plasma Removal
RBC Removal by Density
Gradient
WBC Removal by
Leukocytes Depletion
CTC Staining
CTC Identification
----- End of picture text -----

42

CytoBot™ Cancer & Prenatal Diagnostics

Esophageal Cancer CTC & CEP8 Aneuploidy

==> picture [742 x 278] intentionally omitted <==

----- Start of picture text -----

Merged PanCK CEP8 CD45 Bright Field
Pancreatic Cancer CTC and Plastin-3+ EMT CTC
Merged PanCK CD45 Plastin-3 Nucleus – DAPI
Cytokeratin – FITC CD45 – PE Dual–color FISH
CTC
----- End of picture text -----

Prenatal Circulating fNRBC

==> picture [698 x 17] intentionally omitted <==

----- Start of picture text -----

Merged ECA EMA LCA Nucleus – DAPI
----- End of picture text -----

43

==> picture [794 x 119] intentionally omitted <==

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

44